StatBite: New drug approvals in Japan: a comparison of review times and number of employees

No authors listed

Comparative Study

No authors listed. J Natl Cancer Inst. 2010.

. 2010 Feb 3;102(3):150.

doi: 10.1093/jnci/djq006. Epub 2010 Jan 27.

No abstract available

Similar articles

Clinical development and review times for new drugs in Japan: associated factors.
Ishibashi T, Yasuda K, Kusama M, Sugiyama Y, Ono S. Ishibashi T, et al. Clin Pharmacol Ther. 2010 Oct;88(4):487-91. doi: 10.1038/clpt.2010.108. Epub 2010 Aug 25. Clin Pharmacol Ther. 2010. PMID: 20739921
New drug approval times and clinical evidence in Japan.
Ono S, Yoshioka C, Asaka O, Tamura K, Shibata T, Saito K. Ono S, et al. Contemp Clin Trials. 2005 Dec;26(6):660-72. doi: 10.1016/j.cct.2005.07.003. Epub 2005 Aug 24. Contemp Clin Trials. 2005. PMID: 16122988
[Investigation on new molecular entities of drugs approved in three regions, Japan, U.S. and EU--common and preceding approvals in current 4 years].
Saito M, Hirata-Koizumi M, Miyake S, Hasegawa R. Saito M, et al. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2006;(124):80-2. Kokuritsu Iyakuhin Shokuhin Eisei Kenkyusho Hokoku. 2006. PMID: 17405529 Japanese.
[Review process of new oncology drug application in Japan--role of MD reviewer].
Fujiwara Y. Fujiwara Y. Gan To Kagaku Ryoho. 1999 Jan;26(2 Suppl):196-203. Gan To Kagaku Ryoho. 1999. PMID: 9987519 Review. Japanese.
New drug approval process in Japan.
Hayakawa T. Hayakawa T. Curr Opin Biotechnol. 1999 Jun;10(3):307-11. doi: 10.1016/S0958-1669(99)80055-X. Curr Opin Biotechnol. 1999. PMID: 10361082 Review. No abstract available.